Last reviewed · How we verify
hI-con1
At a glance
| Generic name | hI-con1 |
|---|---|
| Also known as | human Immuno-conjugate 1 |
| Sponsor | Iconic Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability Study for Age-Related Macular Degeneration (PHASE1, PHASE2)
- Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hI-con1 CI brief — competitive landscape report
- hI-con1 updates RSS · CI watch RSS
- Iconic Therapeutics, Inc. portfolio CI